Who owns Personalis, Inc. (PSNL)? Elite investor 13F holders
2 tracked elite investors reported holding Personalis, Inc as of 2026-06-30, including Tudor Investment, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Health Care Equipment & Services
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Tudor Investment | PERSONALIS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 3675901.00 USD | 274321.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | PERSONALIS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Ancora Advisors / Ancora Holdings | PERSONALIS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 9246.00 USD | 690.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.